Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
EUCTR2015-002802-34-Outside-EU/EEA
/ Unknown statusNot ApplicableMulticentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature suffering from somatotropin deficiency (GH) – phase IIIb
100 Clinical Results associated with Sandoz SAS
0 Patents (Medical) associated with Sandoz SAS
100 Deals associated with Sandoz SAS
100 Translational Medicine associated with Sandoz SAS